טוען...
Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells
Although imatinib is effective in chronic myeloid leukemia treatment, imatinib resistance due to the T315I mutation and/or other mutations is a challenge to be overcome. However, how DNA mutation occurs, particularly the T315I mutation, remains unclear. In the current study, the mutagenesis of BCR-A...
שמור ב:
| הוצא לאור ב: | Mol Med Rep |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
D.A. Spandidos
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5779997/ https://ncbi.nlm.nih.gov/pubmed/29152650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2017.7835 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|